You are here

Home » Content

IMPURITY PROFILING OF PHARMACEUTICALS

Journal Name:

  • Advance Research in Pharmaceuticals and Biologicals

Publication Year:

  • 2011

Key Words:

Author Name
Abstract (2. Language): 
Impurity profiling is the process of acquiring and evaluating data that establishes biological safety of an individual impurity; thus, revealing its need and scope in pharmaceutical research. There is no clear definition for impurity in the pharmaceutical world. Impurity profiling includes identification, structure elucidation and quantitative determination of impurities and degradation products in bulk drug materials and pharmaceutical formulations. Impurity profiling has gained importance in modern pharmaceutical analysis due to the fact that unidentified, potentially toxic impurities are hazardous to health and in order to increase the safety of drug therapy, impurities should be identified and determined by selective methods. Terms such as residual solvents, byproduct, transformation products, degradation products, interaction products and related products are frequently used to define impurities. Identification of impurities is done by variety of Chromatographic and Spectroscopic techniques, either alone or in combination with other techniques. The advent of hyphenated techniques has revolutionized impurity profiling, by not only separation but structural identification of impurities as well. The present review covers various aspects related to the analytical method development for impurity profiling of an active pharmaceutical ingredient
Bookmark/Search this post with
FULL TEXT (PDF): 
PDF icon arastrmx_160852_1_pp_76-90.pdf
  • 2
76-90
  • English

REFERENCES

References: 

1. S. Ahuja, K. M. Alsante. Handbook of
Isolation and Characterization of
Impurities in Pharmaceuticals, Vol. 5,
Separation Science and Technology,
Academic press, 2003.
2. S. Ahuja. Impurities Evaluation of
Pharmaceuticals, Marcel Dekker, Inc.
New York, 2006.
3. S. Ahuja, S. Scypinski. Handbook of
Modern Pharmaceutical Analysis, Vol.
3, Separation Science and Technology,
Academic press, 2003
4. J. Roy. Pharmaceutical Impurities–a
mini review, AAPS PharmSciTech
3(2): 1-8 (2002).
5. ICH Harmonized Triplicate Guideline:
Impurities in New Drug Substances
Q3A (R2), ICH Steering Committee,
Step 4 of ICH process, 25th Oct. 2006.
6. ICH Harmonized Triplicate Guideline:
Impurities in New Drug Products Q3B
(R2), ICH Steering Committee, Step 4
of ICH process, 2nd June 2006.
7. ICH Harmonized Triplicate Guideline:
Guideline for Residual Solvents Q3C
(R3), ICH Steering Committee, Step 4
of ICH process, Nov 2005.
8. S. Gorog, M. Babjak, and G. Balogh.
Drug impurity profiling strategies,
Talanta 44: 1517-1526 (1997).
9. www.pharmainfo.net/exclusive/reviews
/impurity_profile:_a_review/
10. www.pharmainfo.net/exclusive/reviews
/impurity_profile_of_active_pharmaceu
tical_ingredient_:_a_review/
Anita Ayre et al:, ARPB, 2011; Vol 1(2) ISSN 2250 - 0744
(Review Article)
www.arpb.info Page 88
11. S. Ahuja. Assuring quality of drugs by
monitoring impurities, Advanced drug
delivery reviews 59: 3-11(2007).
12. K. M. Alsante, T. D. Hatajik, L. L.
Lohr, and T. R. Sharp T. R. Isolation
and identification of process related
impurities and degradation products
from pharmaceutical drug candidates.
Part I, American Pharmaceutical
Review 4(1): 70-78 (2001).
13. L. L. Lohr, R. S. Thomas, K. M.
Alsante, T. D. Hatajik. Isolation and
identification of process related
impurities and degradation products
from pharmaceutical drug candidates.
Part II- The roles of NMR and Mass
Spectrormetry, American
Pharmaceutical Review Fall issue: 2-7
(2001).
14. J. D. Orr, S. Krull, M. E. Swartz.
Validation of Impurity Methods, Part I,
LCGC North America 21(7): 626-633
(2003).
15. J. D. Orr, S. Krull, M. E. Swartz.
Validation of Impurity Methods. Part II,
LCGC North America 21(12): 1146-
1152 (2003).
16. S. Gorog. The importance and
challenges of impurity profiling in
modern pharmaceuticals, Trends in
analytical chemistry 24(8): 755-757
(2006).
17. N. Grekas. Organic impurities in
chemical drug substances,
Pharmaceutical Technology Europe:
24-32 (2005).
18. ICH Harmonized Triplicate Guideline:
Stability Testing of New Drug
Substances and Products Q1A (R2),
ICH Steering Committee, Step 4 of ICH
process, 6th Feb, 2003.
19. ICH Harmonized Triplicate Guideline:
Stability Testing: Photostability Testing
of New Drug Substances and Products
Q1B (R2), ICH Steering Committee,
Step 4 of ICH process, November 1996.
20. ICH Harmonized Triplicate Guideline:
Validation of Analytical Procedures:
Text and Methodology Q2 (R1), ICH
Steering Committee, Step 4 of ICH
process, November 2005.
21. US-FDA Guidelines, NDAs: Impurities
in New Drug Substances.
22. US-FDA Guidelines, ANDAs:
Impurities in New Drug Substances.
23. Australian Regulatory Guidelines for
Prescription Medicines - Impurities in
Active Pharmaceutical Ingredients and
Finished Products, Therapeutic
Governance Authority (TGA),
Australia.
24. The United States Pharmacopoeia 24th
National Formulary 19, General
Information (1225), Validation of
Compendial Methods (United States
Pharmacopoeial convention, Inc.,
Rockville, Maryland: 2150-2151
(1999).
Anita Ayre et al:, ARPB, 2011; Vol 1(2) ISSN 2250 - 0744
(Review Article)
www.arpb.info Page 89
25. Drafts Guidance for Industry:
Analytical Procedures and Method
Validation (U.S. Department of Health
and Human Services, Foods and Drug
Administration, Center of Drug
Evaluation and Research, Center of
Biologics division of Research,
Rockville, Maryland (2000).
26. M. Hindle, P. R. Byron, S. Hou. A
Stability-indicating HPLC assay
method for Budensonide, Jr. of
Pharmaceutical and Biomedical
Analysis 24: 371-380 (2001).
27. R. Dandala. Isolation, Structural
elucidation and Characterization of
impurities in Cefdinir, Jr. of
Pharmaceutical and Biomedical
Analysis 43: 1476-1482 (2007).
28. K. Vyas. Identification and
characterization of potential impurities
of Donepezil, Jr. of Pharmaceutical and
Biomedical Analysis 35: 1047-1058
(2004).
29. K. Vyas. Isolation and characterization
of process-related impurities in
Linezolid, Jr. of Pharmaceutical and
Biomedical Analysis 30: 635-642
(2002).
30. K. Vyas. Impurity profile study of
Loratadine, Jr. of Pharmaceutical and
Biomedical Analysis 32: 29-39 (2003).
31. K. Vyas. Impurity profile study of
Repaglinide, Jr. of Pharmaceutical and
Biomedical Analysis 32: 461-467
(2003).
32. K. Vyas. Isolation and characterization
of process-related impurities in
Rofecoxib, Jr. of Pharmaceutical and
Biomedical Analysis 29: 355-360
(2002).
33. R. Dandala. Impurity profile study of
Zaleplon, Jr. of Pharmaceutical and
Biomedical Analysis 44: 101-109
(2007).
34. British Pharmacopoeia, The
Department of Health, Social Services
and Public Safety 2004.
35. Indian Pharmacopoeia Government of
India, Ministry of Health and Family
Welfare. Published by the Controller of
Publications, Delhi 1996.
36. United State Pharmacopeia The
National Formulary. Asian Edition
2004.
37. Z. Halmos, C. Szantay, J. J. Brlik, A.
Csehi, K. Varga, P. Horvath, M.
Kislaki, G. Domani, A. Nemes and S.
Gorog. Estimation of impurity profile
of drugs and related materials, Part 15.
Identification of minor impurities in
cimetidine, J Pharm Biomed Anal 15: 1
(1996).
38. P. Horvath, G. Balogh, J. Brlik, A.
Csehi, F. Dravecz, Z. Halmos, A.
Lauko, M. Renyei, K. Varga and S.
Gorog. Estimation of impurity profile
of drugs and related materials Part 16:
Anita Ayre et al:, ARPB, 2011; Vol 1(2) ISSN 2250 - 0744
(Review Article)
www.arpb.info Page 90
identification of the side-products of the
ethinylation step in the synthesis of
contraceptive gestogens, J Pharm
Biomed Anal 15:1343 (1997).
39. U. Satyanarayana, D. Sreenivas Rao, Y.
Ravindra Kumar, J. Moses Babu, P.
Rajender Kumar and J. Tirupathi
Reddy. Isolation, synthesis and
characterization of impurities in
celecoxib a COX-2 inhibitor, J Pharm
Biomed Anal 35: 951 (2004).
40. M. Babjak, G. Balogh, M. Gazdag and
S. Gorog. Estimation of impurity
profile of drugs and related materials
Part XXI. HPLC/UV/MS study of the
impurity profile of ethynodiol diacetate,
J Pharm Biomed Anal 29:1153 (2002).
41. P. Vichet, S. Narini, P. Juthamard, P.
Wiphada, S. Tetsuro and T. Ken.
Idetification of impurities and statistical
classification of methamphetamine
tablets (Ya-Ba) seized in Thailand,
Forensic Science International 126:105
(2002).
42. K V S R Krishna Reddy, J. Moses
Babu, T. M. Vijayvitthal, S. Eswaraiah,
M. Satyanarayana Reddy, P. K. Dubey
and K. Vyas. Impurity profile study of
morphine, J Pharm Biomed Anal
32:461 (2003).
43. R. Dams, T. Benijts, W. Lambert, D.
Massart and A. De Leenheer. Heroin
impurity profiling: trends throughout a
decade of experimenting-Review,
Forensic Science International 121:81
(2001).

Thank you for copying data from http://www.arastirmax.com